Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model

Journal of Lipid Research

Volumn 51, Issue 4, 2010, Pages 763-770

  Briand, François ^a   Tréguier, Morgan ^b   André, Agnès ^a,b   Grillot, Didier ^c   Issandou, Marc ^c   Ouguerram, Khadija ^b   Sulpice, Thierry ^a  

^a Physiogenex SAS   (France)

^b HÔTEL DIEU   (France)

^c ULIS   (France)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; Dyslipidemia; Lipoprotein

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; CHOLESTEROL; CHOLESTEROL OLEATE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; TRIACYLGLYCEROL; TRITIUM; VERY LOW DENSITY LIPOPROTEIN; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; BILE ACID; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; ORPHAN NUCLEAR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG TARGETING; DYSLIPIDEMIA; FATTY LIVER; FECES LEVEL; HAMSTER; ISOTOPE LABELING; LIPOPROTEIN METABOLISM; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; TREATMENT DURATION; AGONISTS; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; CELL LINE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DYSLIPIDEMIAS; FECES; GENE EXPRESSION REGULATION; GENETICS; INTESTINE ABSORPTION; LIPID METABOLISM; LIVER; MESOCRICETUS; METABOLISM; MOUSE; TIME; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BENZOATES; BENZYLAMINES; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CELL LINE; CHOLESTEROL; CRICETINAE; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FATTY LIVER; FECES; GENE EXPRESSION REGULATION; INTESTINAL ABSORPTION; LIPID METABOLISM; LIPOPROTEINS; LIPOPROTEINS, HDL; LIVER; MACROPHAGES; MESOCRICETUS; MICE; ORPHAN NUCLEAR RECEPTORS; RNA, MESSENGER; TIME FACTORS;

EID: 77950605567     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M001552     Document Type: Article

References (36)

1. Fiévet, C., and B. Staels. 2009. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem. Pharmacol. 77: 1316-1327.
2. Naik, S. U., X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader. 2006. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 113: 90-97.
3. Calpe-Berdiel, L., N. Rotllan, C. Fiévet, R. Roig, F. Blanco-Vaca, and J. C. Escolà-Gil. 2008. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8. J. Lipid Res. 49: 1904-1911.
4. Rader, D. J., E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat. 2009. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50 (Suppl): S189-S194.
5. Repa, J. J., and D. J. Mangelsdorf. 2002. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 8: 1243-1248.
6. Wang, N., M. Ranalletta, F. Matsuura, F. Peng, and A. R. Tall. 2006. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass effl ux to HDL. Arterioscler. Thromb. Vasc. Biol. 26: 1310-1316.
7. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99: 7604-7609.
8. Levin, N., E. D. Bischoff, C. L. Daige, D. Thomas, C. T. Vu, R. A. Heyman, R. K Tangirala, and I. G. Schulman. 2005. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25: 135-142.
9. Rader, D. J. 2007. Liver X receptor and farnesoid X receptor as therapeutic targets. Am. J. Cardiol. 100: n 15-19.
10. Miao, B., S. Zondlo, S. Gibbs, D. Cromley, V. P. Hosagrahara, T. G. Kirchgessner, J. Billheimer, and R. Mukherjee. 2004. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 45: 1410-1417.
11. Groot, P. H., N. J. Pearce, J. W. Yates, C. Stocker, C. Sauermelch, C. P. Doe, R. N. Willette, A. Olzinski, T. Peters, D. d'Epagnier, et al. 2005. Synthetic LXR agonists increase LDL in CETP species. J. Lipid Res. 46: 2182-2191.
12. Wrobel, J., R. Steffan, S. M. Bowen, R. Magolda, E. Matelan, R Unwalla, M. Basso, V. Clerin, S. J. Gardell, P. Nambi, et al. 2008. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J. Med. Chem. 51: 7161-7168.
13. Quinet, E.M., M.D. Basso, A.R. Halpern, D.W. Yates, RJ. Sheffan, V. Clerin, C. Resmini, J.C. Keith, T.J. Berrodin et al. 2009. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J. Lipid Res. 50: 2358-2370.
14. Duan, L. P., H. H. Wang, A. Ohashi, and D. Q. Wang. 2006. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G269-G276.
15. Briand, F., T. Magot, M. Krempf, P. Nguyen, and K Ouguerram. 2006. Effects of atorvastatin on high-density lipoprotein apolipo-protein A-I metabolism in dogs. Eur. J. Clin. Invest. 36: 224-230.
16. Briand, F., S. U. Naik, I. Fuki, J. S. Millar, C. MacPhee, M. Walker, J. Billheimer, G. Rothblat, and D. J. Rader. 2009. Both the peroxisome proliferator-activated receptor 8 agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin. Trans. Sci. 2: 127-133.
17. Woollett, L. A., and D. K Spady. 1997. Kinetic parameters for high density lipoprotein apoprotein AI and cholesteryl ester transport in the hamster. J. Clin. Invest. 99: 1704-1713.
18. Lewis, G. F., S. Murdoch, K. Uffelman, M. Naples, L. Szeto, A. Albers, K. Adeli, and J. D. Brunzell. 2004. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes. 53: 2893-2900.
19. Liu, G. L., L. M. Fan, and R. N. Redinger. 1991. The association of hepatic apoprotein and lipid metabolism in hamsters and rats. Comp. Biochem. Physiol. A Comp. Physiol. 99: 223-228.
20. Tchoua, U., W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov. 2008. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc. Res. 77: 732-739.
21. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D. J. Mangelsdorf, et al. 2000. Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838.
22. Bilz, S., V. Samuel, K. Morino, D. Savage, C. S. Choi, and G. I. Shulman. 2006. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290: E716-E722.
23. Wang, P. R., Q. Guo, M. Ippolito, M. Wu, D. Milot, J. Ventre, T. Doebber, S. D. Wright, and Y. S. Chao. 2001. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur. J. Pharmacol. 427: 285-293.
24. Basciano, H., A. E. Miller, M. Naples, C. Baker, R. Kohen, E. Xu, Q. Su, E. Allister, M. Wheeler et al. 2009. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab. 297: E462-473.
25. Hsieh, J., A. A. Hayashi, J. Webb, and K. Adeli. 2008. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atheroscler. Suppl. 9: 7-13.
26. Zelcer, N., C. Hong, R. Boyadjian, and P. Tontonoz. 2009. LXR regulates cholesterol uptake through idol-dependent ubiquitina-tion of the LDL receptor. Science. 325: 100-104.
27. Basciano, H., A. E. Miller, C. Baker, M. Naples and K. Adeli. 2009. LXR alpha activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G323-332.
28. Repa, J. J., K. E. Berge, C. Pomajzl, J. A. Richardson, H. Hobbs, and D. J. Mangelsdorf. 2002. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277: 18793-18800.
29. Yu, L., J. York, K. von Bergmann, D. Lutjohann, J. C. Cohen, and H. H. Hobbs. 2003. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J. Biol. Chem. 278: 15565-15570.
30. Sehayek, E., and S. L. Hazen. 2008. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler. Thromb. Vasc. Biol. 28: 1296-1297.
31. Duval, C., V. Touche, A. Tailleux, J. C. Fruchart, C. Fievet, V. Clavey, B. Staels, and S. Lestavel. 2006. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem. Biophys. Res. Commun. 340: 1259-1263.
32. Kruit, J. K., A. K. Groen, T. J. van Berkel, and F. Kuipers. 2006. Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol. 12: 6429-6439.
33. Kruit, J. K., T. Plösch, R. Havinga, R. Boverhof, P. H. Groot, A. K. Groen, and F. Kuipers. 2005. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology. 128: 147-156.
34. van der Veen, J. N., T. H. van Dijk, C. L. Vrins, H. van Meer, R. Havinga, K. Bijsterveld, U. J. Tietge, A. K. Groen, and F. Kuipers. 2009. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284: 19211-19219.
35. van der Velde, A. E., C. L. Vrins, K. van den Oever, C. Kunne, R. P. Oude Elferink, F. Kuipers, and A. K. Groen. 2007. Direct intestinal cholesterol secretion contributes signifi cantly to total fecal neutral sterol excretion in mice. Gastroenterology. 133: 967-975.
36. Fu, L., L. M. John, S. H. Adams, X. X. Yu, E. Tomlinson, M. Renz, P. M. Williams, R. Soriano, R. Corpuz, B. Moffat, et al. 2004. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-defi cient diabetes. Endocrinology. 145: 2594-2603.